Expanding the public health research agenda for ovarian cancer

Journal of Women's Health

Volumn 18, Issue 9, 2009, Pages 1299-1305

  Trivers, Katrina F ^a   Stewart, Sherri L ^a   Peipins, Lucy ^a   Rim, Sun Hee ^a   White, Mary C ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AWARENESS; CANCER SURVIVOR; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; GENETIC SCREENING; HEALTH CARE ORGANIZATION; HEALTH CARE QUALITY; HEALTH SERVICE; HUMAN; MEDICAL EXPERT; MEDICAL RESEARCH; OVARY CANCER; PATIENT CARE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW;

CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH PROMOTION; HEALTH SERVICES RESEARCH; HUMANS; OVARIAN NEOPLASMS; PATIENT EDUCATION AS TOPIC; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; QUALITY OF HEALTH CARE; UNITED STATES; WOMEN'S HEALTH; WOMEN'S HEALTH SERVICES;

EID: 70349224035     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2009.1622     Document Type: Review

References (62)

1. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999-2005 incidence and mortality Web-based report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2009. Available at www.cdc.gov/uscs
2. Jemal A, Thun MJ, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008;100:1672-1694.
3. Ries LAG, Melbert D, Krapcho M, et al., eds. SEER cancer statistics review, 1975-2005. Bethesda, MD: National Cancer Institute:, 2008. Available at seer.cancer.gov/csr/1975-2005/, based on November 2007 SEER data submission, posted to the SEER website, 2008.
4. Eheman CR, Peipins L, Wynn M, et al. Development of a public health research program for ovarian cancer. J Womens Health 2006;15:339-345.
5. Ioannidis JP. Personalized genetic prediction: Too limited, too expensive, or too soon? Ann Intern Med 2009;150:139-141.
6. Hunter DJ, Khoury MJ, Drazen JM. Letting the genome out of the bottle-Will we get our wish? N Engl J Med 2008;358: 105-107.
7. Feero WG, Guttmacher AE, Collins FS. The genome gets personal-almost. JAMA 2008;299:1351-1352.
8. Hedgecoe A. The politics of personalized medicine: Pharmacogenetics in the clinic. Cambridge, UK: Cambridge University Press, 2004.
9. Jain KK. Personalized medicine. Curr Opin Mol Ther 2002;4:548-558.
10. Hood E. Pharmacogenomics: The promise of personalized medicine. Environ Health Perspect 2003;111:A581-589.
11. Roses AD. Pharmacogenetics and future drug development and delivery. Lancet 2000;355:1358-1361.
12. Haddow JE, Palomaki GE. Population-based prenatal screening for cystic fibrosis via carrier testing: ACCE review. Available at www.cdc.gov/genomics/ activities/FBR/ACCE.htm Accessed November 2008.
13. Ransohoff DF. Lessons from controversy: Ovarian cancer screening and serum proteomics. J Natl Cancer Inst 2005;97: 315-319.
14. Offit K. Genomic profiles for disease risk: Predictive or premature? JAMA 2008;299:1353-1355.
15. Teutsch SM, Bradley LA, Palomaki GE, et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: Methods of the EGAPP Working Group. Genet Med 2009;11:3-14.
16. Visintin I, Feng Z, Longton G, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008;14: 1065-1072.
17. Coates RJ, Kolor K, Stewart SL, Richardson LC. Diagnostic markers for ovarian cancer screening: Not ready for routine clinical use. Clin Cancer Res 2008;14:7575-7576; author reply 7577-7579.
18. Greene MH, Feng Z, Gail MH. The importance of test positive predictive value in ovarian cancer screening. Clin Cancer Res 2008;14:7574; author reply 7577-7579.
19. McIntosh M, Anderson G, Drescher C, et al. Ovarian cancer early detection claims are biased. Clin Cancer Res 2008;14: 7574; author reply 7577-7579.
20. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359:572-577.
21. Rockhill B. Proteomic patterns in serum and identification of ovarian cancer. Lancet 2002;360:169; author reply 170-171.
22. Nelson HD, Huffman LH, Fu R, Harris EL. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: Systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2005;143: 362-379.
23. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-1130.
24. U.S. Preventive Services Task Force. Screening for ovarian cancer: Recommendation statement. Am Fam Physician 2005;71:759-762.
25. Scheuner MT, Sieverding P, Shekelle PG. Delivery of genomic medicine for common chronic adult diseases: a systematic review. JAMA 2008;299:1320-1334.
26. Buys SS, Partridge E, Greene MH, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: Findings from the initial screen of a randomized trial. Am J Obstet Gynecol 2005;193: 1630-1639. (Pubitemid 41540458)
27. Partridge E, Kreimer AR, Greenlee RT, et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol 2009;113:775-782.
28. Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: Results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009;10:327-340.
29. Kobayashi H, Yamada Y, Sado T, et al. A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int J Gynecol Cancer 2008;18:414-420.
30. Lacey JV Jr, Greene MH, Buys SS, et al. Ovarian cancer screening in women with a family history of breast or ovarian cancer. Obstet Gynecol 2006;108:1176-1184.
31. van der Velde NM, Mourits MJ, Arts HJ, et al. Time to stop ovarian cancer screening in BRCA1/2 mutation carriers? Int J Cancer 2009;124:919-923.
32. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingooophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009;101:80-87.
33. Domchek SM, Friebel TM, Neuhausen SL, et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 2006;7:223-229.
34. Stewart SL, Thompson TD, Wike JM, et al. Descriptive epidemiology, treatment and survival of low-grade and high-grade serous adenocarcinoma of the ovary. Gynecol Oncol 2009;112(Suppl 1):S124.
35. Cress RD, Bauer K, O'Malley CD, et al. Surgical staging of early-stage epithelial ovarian cancer. Gynecol Oncol 2009;112(Suppl 1):S154.
36. Stewart SL, Wike JM, Cress RD, et al. Ovarian cancer treatment patterns and outcomes in the United States: a National Program of Cancer Registries Study. J Clin Oncol 2006;24(18S):15031.
37. Fader AN, Rose PG. Role of surgery in ovarian carcinoma. J Clin Oncol 2007;25:2873-2883.
38. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248-1259.
39. Markman M. Concept of optimal surgical cytoreduction in advanced ovarian cancer: a brief critique and a call for action. J Clin Oncol 2007;25:4168-4170.
40. Earle CC, Schrag D, Neville BA, et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 2006;98:172-180.
41. Goff BA, Matthews BJ, Wynn M, Muntz HG, Lishner DM, Baldwin LM. Ovarian cancer: Patterns of surgical care across the United States. Gynecol Oncol 2006;103:383-390.
42. Chan JK, Kapp DS, Shin JY, et al. Factors associated with the suboptimal treatment of women less than 55 years of age with early-stage ovarian cancer. Gynecol Oncol 2008;108:95-99.
43. Giede KC, Kieser K, Dodge J, Rosen B. Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol 2005;99:447-461.
44. Colombo N, Gore M. Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy. Crit Rev Oncol Hematol 2007;64:129-138.
45. Prasad M, Ben-Porat L, Hoppe B, et al. Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer. Gynecol Oncol 2004;93: 223-228.
46. Rarick M. Treating advanced ovarian cancer within the health maintenance organization: a Kaiser Permanente approach. Semin Oncol 1999;26:52-58.
47. Pollard WE. Use of consumer panel survey data for public health communication planning; An evaluation of survey results. In: Proceedings of the section on health policy statistics. Alexandria, VA: American Statistical Association, 2002:2720-2724.
48. Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 2004;291:2705-2712.
49. Wynn ML, Chang S, Peipins LA. Temporal patterns of conditions and symptoms potentially associated with ovarian cancer. J Womens Health 2007;16:971-986.
50. Ryerson AB, Eheman C, Burton J, et al. Symptoms, diagnoses, and time to key diagnostic procedures among older U.S. women with ovarian cancer. Obstet Gynecol 2007;109: 1053-1061.
51. Bankhead CR, Collins C, Stokes-Lampard H, et al. Identifying symptoms of ovarian cancer: a qualitative and quantitative study. Br J Obstet Gynaecol 2008;115:1008-1014.
52. Landen CN Jr., Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 2008;26:995-1005.
53. Shih IeM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004;164:1511-1518.
54. Goff BA, Mandel LS, Drescher CW, et al. Development of an ovarian cancer symptom index: Possibilities for earlier detection. Cancer 2007;109:221-227.
55. Schouten LJ, Rivera C, Hunter DJ, et al. Height, body mass index, and ovarian cancer: a pooled analysis of 12 cohort studies. Cancer Epidemiol Biomarkers Prev 2008;17: 902-912.
56. Hankinson SE, Danforth KN. Ovarian cancer. In: Schottenfeld D, Fraumeni JF, eds. Cancer epidemiology and prevention, 3rd ed. Oxford: Oxford University Press, 2006: 1013-1026.
57. Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Doll R, Hermon C, Peto R, Reeves G. Ovarian cancer and oral contraceptives: Collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008;371:303-314.
58. Beral V, Bull D, Green J, Reeves G. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 2007;369:1703-1710. (Pubitemid 46755369)
59. Mills PK, Riordan DG, Cress RD, Goldsmith DF. Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk. Cancer Detect Prev 2005;29:124-132.
60. Lorenzo Bermejo J, Rawal R, Hemminki K. Familial association of specific histologic types of ovarian malignancy with other malignancies. Cancer 2004;100:1507-1514.
61. Goodman MT, Shvetsov YB. Incidence of ovarian, peritoneal, and fallopian tube carcinomas in the United States, 1995-2004. Cancer Epidemiol Biomarkers Prev 2009; 18:132-139.
62. Stewart SL, Wike JM, Foster SL, Michaud F. The incidence of primary fallopian tube cancer in the United States. Gynecol Oncol 2007;107:392-397.